stockrow
Friday 6 November 2026
Export BCRX’s income statement to Excel — free account
BioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
7.51
0.12
−1.57%
Follow BCRX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
6.24 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.87 | 2.60 | 2.71 | 2.21 | |
P/FCF ratio |
4.74 | 7.42 | 6.81 | 5.81 | |
P/Operating CF |
5.61 | (37.32) | 24.39 | 64.56 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.11 | 3.30 | 3.22 | 2.72 | |
EV/EBITDA |
5.45 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
5.31 | 9.35 | 8.06 | 7.12 | |
EV/FCF |
5.34 | 9.41 | 8.11 | 7.14 | |
Quick Ratio |
1.95 | 1.78 | 2.22 | 0.62 | |
Current Ratio |
2.06 | 1.91 | 2.32 | 2.71 | |
Net Debt/EBITDA |
0.79 | (0.89) | 4.92 | — | |
Debt/Assets |
93.53% | 184.94% | 150.47% | 0.00% | |
Debt/Equity |
(4.04) | (1.55) | (1.85) | 0.00 | |
Asset Turnover |
1.74 | 1.87 | 1.85 | 1.85 | |
Operating CF/Net income |
1.19 | 0.09 | 1.33 | 0.87 | |
Capex/Depreciation |
0.36 | (0.28) | (0.70) | 0.00 | |
Interest Coverage |
18.42 | (35.47) | 4.54 | 2.52 | |
Research and Development Expense of Revenue |
10.05% | 38.56% | 23.81% | 32.29% | |
Selling, General and Administrative Expense of Revenue |
23.56% | 60.45% | 29.31% | 37.26% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.85% | 10.25% | 6.73% | 7.90% | |
Graham Net Nets |
(0.14) | (0.28) | (0.21) | (0.21) | |
Graham Number |
0.00 | 9.43 | 7.61 | 6.87 | |
Earnings Yield |
16.03% | (18.17%) | (14.40%) | (16.21%) | |
Free Cash Flow Yield |
21.10% | 13.48% | 14.69% | 17.21% | |
Revenue per Share |
1.94 | 0.65 | 0.86 | 0.71 | |
Operating CF per Share |
1.39 | (0.26) | 0.41 | 0.13 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
1.39 | (0.26) | 0.41 | 0.13 | |
Cash per Share |
1.31 | 0.99 | 1.39 | 0.00 | |
Shareholders Equity per Share |
(0.57) | (2.29) | (1.79) | (1.55) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.57) | (2.29) | (1.79) | (1.55) | |
Free Cash Flow |
291.71 | (62.19) | 104.13 | 32.75 | |
Working Capital |
208.28 | 178.23 | 275.84 | 335.32 | |
Capital Expenditures |
(0.25) | (0.40) | (0.21) | (0.23) | |
Net Current Asset Value |
(228.96) | (645.27) | (527.46) | (457.30) | |
EV/EBIT |
5.41 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
4.80 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
92.94 | 101.33 | 100.97 | 106.56 | |
Average Payables |
13.74 | 10.50 | 10.02 | 10.07 | |
Average Inventory |
6.74 | 6.43 | 5.55 | 9.49 | |
Average Assets |
502.29 | 472.55 | 507.52 | 518.75 | |
Average Common Equity |
(297.54) | (502.88) | (437.94) | (392.64) |
Columns are period end dates · fundamentals updated 4 Nov 2026